Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC

Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified in patients with NSCLC and clinical trials are testing the efficacy of anti-FGFR therapie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tchaicha, Jeremy H., Akbay, Esra A., Altabef, Abigail, Mikse, Oliver R., Kikuchi, Eiki, Rhee, Kevin, Liao, Rachel G., Bronson, Roderick T., Sholl, Lynette M., Meyerson, Matthew, Hammerman, Peter S., Wong, Kwok-Kin
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154986/
https://ncbi.nlm.nih.gov/pubmed/25035393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-3218
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars